The Math Shows QVML Can Go To $41
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2025
0mins
Source: NASDAQ.COM
ETF Analyst Target Prices: The Invesco S&P 500 QVM Multi-factor ETF (QVML) has an implied analyst target price of $40.78, indicating a potential upside of 17.45% from its current trading price of $34.72. Key holdings with significant upside include GE HealthCare Technologies, Eversource Energy, and C.H. Robinson Worldwide.
Investor Research Considerations: Analysts' optimistic target prices may reflect future expectations but could also lead to downgrades if they are based on outdated information. Investors are encouraged to conduct further research to assess the validity of these targets in light of recent developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GEHC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GEHC
Wall Street analysts forecast GEHC stock price to rise
13 Analyst Rating
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 64.510
Low
80.00
Averages
92.25
High
105.00
Current: 64.510
Low
80.00
Averages
92.25
High
105.00
About GEHC
GE HealthCare Technologies Inc. is a healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first artificial intelligence (AI)-enabled solutions, services and data analytics. Its business segments include Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its AVS segment offers ultrasound, image guided therapies, and interventional solutions with a portfolio that spans the continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment consists of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment develops and produces two types of imaging agents: contrast media and radiopharmaceuticals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of JAVA Stock's 52-Week High and Low Points
- Price Fluctuation Analysis: JAVA's stock has a 52-week low of $63.67 and a high of $78.52, with the latest trade at $77.93, indicating that the stock is nearing its high point, reflecting market optimism about its future performance.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average provides investors with valuable insights for technical analysis, helping to assess long-term trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Liquidity Monitoring: Weekly monitoring of changes in shares outstanding for ETFs allows for the identification of those experiencing significant inflows or outflows, enabling timely adjustments to investment strategies based on market dynamics.
See More
GE HealthCare Launches MIM Contour ProtégéAI+ 2.0 for Enhanced Radiation Therapy
- FDA Approval: GE HealthCare's MIM Contour ProtégéAI+ 2.0 has received 510(k) clearance from the FDA, marking a significant advancement in radiation oncology treatment planning, which is expected to greatly enhance clinical teams' efficiency and enable faster, personalized patient care.
- Technological Innovation: The new version introduces a Magnetic Resonance Brain model and an updated CT Male Pelvis model, expanding clinical capabilities across key anatomical regions, which is anticipated to improve the precision and efficiency of radiation therapy to meet increasingly complex patient needs.
- Process Automation: MIM Contour ProtégéAI+ 2.0 minimizes user interaction by enabling automatic contouring, significantly reducing manual effort and allowing clinical teams to focus more on developing personalized treatment plans, thereby enhancing the quality of patient care.
- Market Outlook: With the rising global cancer incidence, this innovative product from GE HealthCare not only addresses the market demand for efficient radiation therapy but also strengthens its competitive position in the medical technology sector through continuous technological iterations and updates.
See More
FRT vs GEHC Stock Performance Comparison
- Price Dynamics: FRT is currently trading up approximately 0.6%, indicating a degree of market resilience, which may attract investor attention despite overall market uncertainty.
- GEHC Decline: GEHC's stock is down about 1%, reflecting market concerns over its future growth potential, which could impact investor confidence and lead to capital outflows.
- Market Comparison: On the same trading day, the contrasting stock movements of FRT and GEHC highlight FRT's relative strength in the current economic environment, potentially signaling a shift in investor preference.
- Investor Sentiment: The rise of FRT alongside the decline of GEHC may influence investor asset allocation decisions, prompting a reassessment of their investment ratios in these two stocks.
See More
UBS Upgrades GE HealthCare to Neutral Amid Stock Decline
- Rating Upgrade: UBS upgraded GE HealthCare from Sell to Neutral and lowered its price target from $75 to $69, reflecting a reassessment of the company's stock valuation as shares trade near a 52-week low of $64.
- Stock Decline Reasons: GE HealthCare's stock fell approximately 30% following its Q1 earnings report, primarily due to disappointing results with $5.1 billion in quarterly revenue and an adjusted EPS of $0.99, missing the expected $1.05.
- Cost Pressures: Management highlighted that a supplier recall exacerbated margin pressures stemming from rising costs related to memory chips, oil prices, and freight, leaving little room to offset these headwinds in the short term.
- Long-Term Growth Confidence: Despite short-term challenges, GE HealthCare's leadership reaffirmed its long-term growth trajectory at the Bank of America Global Healthcare Conference, anticipating that cost initiatives, pricing actions, and new product launches will help restore margin improvement.
See More
MercadoLibre and GE Healthcare Executives Increase Stock Holdings
- Executive Purchases: MercadoLibre Director Alejandro Nicolas Aguzin disclosed in an SEC filing that he bought 600 shares of MELI at $1,655.93 each on Friday, totaling an investment of $993,556, marking his first purchase in the past twelve months, indicating confidence in the company's future.
- Market Reaction: Following the news of Aguzin's purchase, MercadoLibre's stock rose approximately 2.3% on Wednesday, reflecting a positive market response to insider buying, which may bolster investor confidence in the company's outlook.
- GE Healthcare Purchase: On the same day, GE HealthCare Technologies Director Kevin Lobo purchased $641,800 worth of stock, acquiring 10,000 shares at $64.18 each, demonstrating confidence in the company's growth potential.
- Profit Performance: As of Wednesday, Lobo's investment has yielded a gain of about 2.3%, based on the day's high trading price of $65.63, indicating market optimism for GE HealthCare, which could drive its stock price higher in the future.
See More
Investigation into GE HealthCare's Possible Securities Law Violations
- Poor Financial Performance: GE HealthCare reported adjusted earnings per share of $0.99 for Q1 2026 and lowered its full-year adjusted EPS guidance to a range of $4.80 to $5.00, down from $4.95 to $5.15, indicating a significant decline in profitability.
- Recall Impact: Management disclosed during the earnings call that profit performance was affected by a recall associated with a PDx supplier, and year-over-year margin performance was also impacted by declines in PCS and the PDx supplier issue, highlighting potential risks in supply chain management.
- Significant Stock Drop: Following the earnings report, GE HealthCare's stock price fell by $9.01, or 13.2%, closing at $59.49 per share, which may raise investor concerns regarding the company's future performance.
- Ongoing Legal Investigation: The Law Offices of Howard G. Smith are investigating on behalf of GE HealthCare investors regarding potential violations of federal securities laws, indicating that legal risks could impact the company's reputation and investor confidence.
See More
Analysis of JAVA Stock's 52-Week High and Low Points
- Price Fluctuation Analysis: JAVA's stock has a 52-week low of $63.67 and a high of $78.52, with the latest trade at $77.93, indicating that the stock is nearing its high point, reflecting market optimism about its future performance.
- Technical Analysis Tool: Comparing the latest stock price to the 200-day moving average provides investors with valuable insights for technical analysis, helping to assess long-term trends and potential buying opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade similarly to stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, impacting the liquidity and market performance of the ETF.
- Liquidity Monitoring: Weekly monitoring of changes in shares outstanding for ETFs allows for the identification of those experiencing significant inflows or outflows, enabling timely adjustments to investment strategies based on market dynamics.
See More
GE HealthCare Launches MIM Contour ProtégéAI+ 2.0 for Enhanced Radiation Therapy
- FDA Approval: GE HealthCare's MIM Contour ProtégéAI+ 2.0 has received 510(k) clearance from the FDA, marking a significant advancement in radiation oncology treatment planning, which is expected to greatly enhance clinical teams' efficiency and enable faster, personalized patient care.
- Technological Innovation: The new version introduces a Magnetic Resonance Brain model and an updated CT Male Pelvis model, expanding clinical capabilities across key anatomical regions, which is anticipated to improve the precision and efficiency of radiation therapy to meet increasingly complex patient needs.
- Process Automation: MIM Contour ProtégéAI+ 2.0 minimizes user interaction by enabling automatic contouring, significantly reducing manual effort and allowing clinical teams to focus more on developing personalized treatment plans, thereby enhancing the quality of patient care.
- Market Outlook: With the rising global cancer incidence, this innovative product from GE HealthCare not only addresses the market demand for efficient radiation therapy but also strengthens its competitive position in the medical technology sector through continuous technological iterations and updates.
See More
FRT vs GEHC Stock Performance Comparison
- Price Dynamics: FRT is currently trading up approximately 0.6%, indicating a degree of market resilience, which may attract investor attention despite overall market uncertainty.
- GEHC Decline: GEHC's stock is down about 1%, reflecting market concerns over its future growth potential, which could impact investor confidence and lead to capital outflows.
- Market Comparison: On the same trading day, the contrasting stock movements of FRT and GEHC highlight FRT's relative strength in the current economic environment, potentially signaling a shift in investor preference.
- Investor Sentiment: The rise of FRT alongside the decline of GEHC may influence investor asset allocation decisions, prompting a reassessment of their investment ratios in these two stocks.
See More
UBS Upgrades GE HealthCare to Neutral Amid Stock Decline
- Rating Upgrade: UBS upgraded GE HealthCare from Sell to Neutral and lowered its price target from $75 to $69, reflecting a reassessment of the company's stock valuation as shares trade near a 52-week low of $64.
- Stock Decline Reasons: GE HealthCare's stock fell approximately 30% following its Q1 earnings report, primarily due to disappointing results with $5.1 billion in quarterly revenue and an adjusted EPS of $0.99, missing the expected $1.05.
- Cost Pressures: Management highlighted that a supplier recall exacerbated margin pressures stemming from rising costs related to memory chips, oil prices, and freight, leaving little room to offset these headwinds in the short term.
- Long-Term Growth Confidence: Despite short-term challenges, GE HealthCare's leadership reaffirmed its long-term growth trajectory at the Bank of America Global Healthcare Conference, anticipating that cost initiatives, pricing actions, and new product launches will help restore margin improvement.
See More
MercadoLibre and GE Healthcare Executives Increase Stock Holdings
- Executive Purchases: MercadoLibre Director Alejandro Nicolas Aguzin disclosed in an SEC filing that he bought 600 shares of MELI at $1,655.93 each on Friday, totaling an investment of $993,556, marking his first purchase in the past twelve months, indicating confidence in the company's future.
- Market Reaction: Following the news of Aguzin's purchase, MercadoLibre's stock rose approximately 2.3% on Wednesday, reflecting a positive market response to insider buying, which may bolster investor confidence in the company's outlook.
- GE Healthcare Purchase: On the same day, GE HealthCare Technologies Director Kevin Lobo purchased $641,800 worth of stock, acquiring 10,000 shares at $64.18 each, demonstrating confidence in the company's growth potential.
- Profit Performance: As of Wednesday, Lobo's investment has yielded a gain of about 2.3%, based on the day's high trading price of $65.63, indicating market optimism for GE HealthCare, which could drive its stock price higher in the future.
See More
Investigation into GE HealthCare's Possible Securities Law Violations
- Poor Financial Performance: GE HealthCare reported adjusted earnings per share of $0.99 for Q1 2026 and lowered its full-year adjusted EPS guidance to a range of $4.80 to $5.00, down from $4.95 to $5.15, indicating a significant decline in profitability.
- Recall Impact: Management disclosed during the earnings call that profit performance was affected by a recall associated with a PDx supplier, and year-over-year margin performance was also impacted by declines in PCS and the PDx supplier issue, highlighting potential risks in supply chain management.
- Significant Stock Drop: Following the earnings report, GE HealthCare's stock price fell by $9.01, or 13.2%, closing at $59.49 per share, which may raise investor concerns regarding the company's future performance.
- Ongoing Legal Investigation: The Law Offices of Howard G. Smith are investigating on behalf of GE HealthCare investors regarding potential violations of federal securities laws, indicating that legal risks could impact the company's reputation and investor confidence.
See More
